190 related articles for article (PubMed ID: 21930937)
1. HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer.
Ahmad I; Patel R; Singh LB; Nixon C; Seywright M; Barnetson RJ; Brunton VG; Muller WJ; Edwards J; Sansom OJ; Leung HY
Proc Natl Acad Sci U S A; 2011 Sep; 108(39):16392-7. PubMed ID: 21930937
[TBL] [Abstract][Full Text] [Related]
2. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.
Manda KR; Tripathi P; Hsi AC; Ning J; Ruzinova MB; Liapis H; Bailey M; Zhang H; Maher CA; Humphrey PA; Andriole GL; Ding L; You Z; Chen F
Oncogene; 2016 Jun; 35(25):3282-92. PubMed ID: 26477312
[TBL] [Abstract][Full Text] [Related]
3.
Parisotto M; Grelet E; El Bizri R; Dai Y; Terzic J; Eckert D; Gargowitsch L; Bornert JM; Metzger D
J Exp Med; 2018 Jun; 215(6):1749-1763. PubMed ID: 29743291
[TBL] [Abstract][Full Text] [Related]
4. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
Wang L; Guo X; Wang J; Jiang C; Bosland MC; Lü J; Deng Y
Cancer Prev Res (Phila); 2016 Jan; 9(1):35-42. PubMed ID: 26511486
[TBL] [Abstract][Full Text] [Related]
5. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.
Alimonti A; Nardella C; Chen Z; Clohessy JG; Carracedo A; Trotman LC; Cheng K; Varmeh S; Kozma SC; Thomas G; Rosivatz E; Woscholski R; Cognetti F; Scher HI; Pandolfi PP
J Clin Invest; 2010 Mar; 120(3):681-93. PubMed ID: 20197621
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.
Revandkar A; Perciato ML; Toso A; Alajati A; Chen J; Gerber H; Dimitrov M; Rinaldi A; Delaleu N; Pasquini E; D'Antuono R; Pinton S; Losa M; Gnetti L; Arribas A; Fraering P; Bertoni F; Nepveu A; Alimonti A
Nat Commun; 2016 Dec; 7():13719. PubMed ID: 27941799
[TBL] [Abstract][Full Text] [Related]
7. Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer.
Ahmad I; Mui E; Galbraith L; Patel R; Tan EH; Salji M; Rust AG; Repiscak P; Hedley A; Markert E; Loveridge C; van der Weyden L; Edwards J; Sansom OJ; Adams DJ; Leung HY
Proc Natl Acad Sci U S A; 2016 Jul; 113(29):8290-5. PubMed ID: 27357679
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer induced by loss of Apc is restrained by TGFβ signaling.
Bjerke GA; Pietrzak K; Melhuish TA; Frierson HF; Paschal BM; Wotton D
PLoS One; 2014; 9(3):e92800. PubMed ID: 24651496
[TBL] [Abstract][Full Text] [Related]
9. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
González-Billalabeitia E; Seitzer N; Song SJ; Song MS; Patnaik A; Liu XS; Epping MT; Papa A; Hobbs RM; Chen M; Lunardi A; Ng C; Webster KA; Signoretti S; Loda M; Asara JM; Nardella C; Clohessy JG; Cantley LC; Pandolfi PP
Cancer Discov; 2014 Aug; 4(8):896-904. PubMed ID: 24866151
[TBL] [Abstract][Full Text] [Related]
10. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation.
Thomsen MK; Ambroisine L; Wynn S; Cheah KS; Foster CS; Fisher G; Berney DM; Møller H; Reuter VE; Scardino P; Cuzick J; Ragavan N; Singh PB; Martin FL; Butler CM; Cooper CS; Swain A;
Cancer Res; 2010 Feb; 70(3):979-87. PubMed ID: 20103652
[TBL] [Abstract][Full Text] [Related]
11. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
[TBL] [Abstract][Full Text] [Related]
12. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
13. IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way.
Zhang X; Wang D; Liu B; Jin X; Wang X; Pan J; Tu W; Shao Y
J Exp Clin Cancer Res; 2020 Sep; 39(1):190. PubMed ID: 32938489
[TBL] [Abstract][Full Text] [Related]
14. Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas.
Ebbesen SH; Scaltriti M; Bialucha CU; Morse N; Kastenhuber ER; Wen HY; Dow LE; Baselga J; Lowe SW
Proc Natl Acad Sci U S A; 2016 Mar; 113(11):3030-5. PubMed ID: 26929372
[TBL] [Abstract][Full Text] [Related]
15. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.
Wang G; Lunardi A; Zhang J; Chen Z; Ala U; Webster KA; Tay Y; Gonzalez-Billalabeitia E; Egia A; Shaffer DR; Carver B; Liu XS; Taulli R; Kuo WP; Nardella C; Signoretti S; Cordon-Cardo C; Gerald WL; Pandolfi PP
Nat Genet; 2013 Jul; 45(7):739-746. PubMed ID: 23727861
[TBL] [Abstract][Full Text] [Related]
16. Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression.
Patel R; Gao M; Ahmad I; Fleming J; Singh LB; Rai TS; McKie AB; Seywright M; Barnetson RJ; Edwards J; Sansom OJ; Leung HY
J Clin Invest; 2013 Mar; 123(3):1157-75. PubMed ID: 23434594
[TBL] [Abstract][Full Text] [Related]
17. Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis.
Guccini I; Revandkar A; D'Ambrosio M; Colucci M; Pasquini E; Mosole S; Troiani M; Brina D; Sheibani-Tezerji R; Elia AR; Rinaldi A; Pernigoni N; Rüschoff JH; Dettwiler S; De Marzo AM; Antonarakis ES; Borrelli C; Moor AE; Garcia-Escudero R; Alajati A; Attanasio G; Losa M; Moch H; Wild P; Egger G; Alimonti A
Cancer Cell; 2021 Jan; 39(1):68-82.e9. PubMed ID: 33186519
[TBL] [Abstract][Full Text] [Related]
18. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
Toso A; Revandkar A; Di Mitri D; Guccini I; Proietti M; Sarti M; Pinton S; Zhang J; Kalathur M; Civenni G; Jarrossay D; Montani E; Marini C; Garcia-Escudero R; Scanziani E; Grassi F; Pandolfi PP; Catapano CV; Alimonti A
Cell Rep; 2014 Oct; 9(1):75-89. PubMed ID: 25263564
[TBL] [Abstract][Full Text] [Related]
19. A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1.
Rodriguez OC; Lai EW; Vissapragada S; Cromelin C; Avetian M; Salinas P; Ramos H; Kallakury B; Casimiro M; Lisanti MP; Tanowitz HB; Pacak K; Glazer RI; Avantaggiati M; Albanese C
Am J Pathol; 2009 Jun; 174(6):2051-60. PubMed ID: 19443706
[TBL] [Abstract][Full Text] [Related]
20. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis.
Chen Z; Carracedo A; Lin HK; Koutcher JA; Behrendt N; Egia A; Alimonti A; Carver BS; Gerald W; Teruya-Feldstein J; Loda M; Pandolfi PP
Sci Signal; 2009 Aug; 2(84):ra44. PubMed ID: 19690330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
